Loading company…
VectorY Therapeutics develops gene therapies and vectorized antibodies for muscular and neurological disorders.
Founded in 2020 and based in Amsterdam, Netherlands, VectorY Therapeutics develops gene therapies for muscular and neurodegenerative disorders, including vectorized antibodies for CNS and somatic conditions. In November 2023, it raised EUR 129 million in Series A funding co-led by EQT Life Sciences and Forbion, with BioGeneration Ventures, Insight Partners, MRL Ventures Fund, and SUNU Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in